QIAGEN Return on Tangible Equity 2010-2022 | QGEN

Current and historical return on tangible equity values for QIAGEN (QGEN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
QIAGEN Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $0.54B $0.29B 534.00%
2021-12-31 $0.51B $0.12B -3200.00%
2021-09-30 $0.60B $0.02B -502.95%
2021-06-30 $0.48B $-0.02B -221.45%
2021-03-31 $0.45B $-0.18B -187.08%
2020-12-31 $0.36B $-0.29B -144.87%
2020-09-30 $0.19B $-0.37B -81.88%
2020-06-30 $0.01B $-0.12B -6.52%
2020-03-31 $-0.03B $-0.22B 13.63%
2019-12-31 $-0.04B $-0.24B 17.96%
2019-09-30 $-0.03B $-0.29B 15.97%
2019-06-30 $0.20B $-0.17B -183.61%
2019-03-31 $0.19B $-0.22B -186.14%
2018-12-31 $0.19B $0.05B -603.17%
2018-09-30 $0.09B $-0.09B -240.54%
2018-06-30 $0.08B $-0.14B -1400.00%
2018-03-31 $0.05B $0.06B 257.14%
2017-12-31 $0.04B $0.03B -213.33%
2017-09-30 $0.09B $0.03B 1780.00%
2017-06-30 $0.08B $-0.04B 447.06%
2017-03-31 $0.08B $-0.10B 200.00%
2016-12-31 $0.08B $0.12B 85.94%
2016-09-30 $0.12B $0.08B 160.52%
2016-06-30 $0.12B $0.06B 184.27%
2016-03-31 $0.13B $0.11B 241.90%
2015-12-31 $0.13B $0.06B 1209.30%
2015-09-30 $0.10B $0.04B 1386.67%
2015-06-30 $0.11B $0.00B 251.50%
2015-03-31 $0.11B $-0.06B 169.29%
2014-12-31 $0.12B $0.04B 109.09%
2014-09-30 $0.15B $0.18B 130.17%
2014-06-30 $0.16B $0.10B 216.55%
2014-03-31 $0.07B $0.11B 150.79%
2013-12-31 $0.07B $0.08B 132.69%
2013-09-30 $0.05B $0.00B 78.01%
2013-06-30 $0.04B $0.01B 45.75%
2013-03-31 $0.12B $0.12B 169.01%
2012-12-31 $0.13B $0.11B 226.32%
2012-09-30 $0.09B $0.07B 298.36%
2012-06-30 $0.10B $-0.02B 303.13%
2012-03-31 $0.10B $0.07B 61.88%
2011-12-31 $0.10B $0.01B 39.22%
2011-09-30 $0.13B $0.07B 39.26%
2011-06-30 $0.13B $0.48B 33.71%
2011-03-31 $0.14B $0.42B 39.71%
2010-12-31 $0.14B $0.37B 47.33%
2010-09-30 $0.15B $0.31B 58.02%
2010-06-30 $0.15B $0.30B 61.35%
2010-03-31 $0.15B $0.24B 130.94%
2009-12-31 $0.14B $0.20B -569.07%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00